#United States #New York #Faruqi & Faruqi #Investors Alert #Jasper Therapeutics

Shareholder Reminder: Investigating Claims Against Jasper Therapeutics

Faruqi & Faruqi, LLP, a recognized national securities law firm, has initiated an investigation to determine if there are potential claims related to Jasper Therapeutics, Inc. (NASDAQ: JSPR). The firm is reaching out to investors who may have suffered financial losses while acquiring securities of Jasper between November 30, 2023, and July 3, 2025.

Jasper Therapeutics has recently come under scrutiny after the company released troubling information regarding its clinical trials and product quality control measures. Allegations have surfaced that Jasper and its executives failed to maintain adequate controls and procedures required for third-party manufacturers to produce drugs in compliance with current Good Manufacturing Practices (cGMP). This lack of compliance raises significant concerns about the reliability of ongoing studies and, consequently, the regulatory and commercial prospects of its flagship product, briquilimab.

On July 7, 2025, following the disclosure of adverse data from the BEACON Study, Jasper’s stock price plummeted by 55.1%, closing at $3.04 per share. The press release from the company disclosed that certain dosages were confounded due to issues with one specific drug product lot, impacting 10 out of 13 patients treated. Furthermore, Jasper announced a suspension of its clinical trials for asthma and Severe Combined Immunodeficiency (SCID), citing the need to redirect resources to advance briquilimab's development for Chronic Spontaneous Urticaria (CSU).

These developments have raised significant alarm among shareholders. Faruqi & Faruqi encourages anyone who invested in Jasper during the specified period and feels they might have suffered losses to reach out directly for a consultation. Specifically, Josh Wilson, a senior partner at the firm, is inviting affected investors to discuss their legal options. Ridgewood shareholders are also informed about the impending deadline of November 18, 2025, to seek the role of lead plaintiff in a federal securities class action against the company.

The firm not only aids investors with claims against companies like Jasper but also seeks to provide insights and guidance for individuals impacted by misleading corporate communications. Their commitment to protecting investors' rights has seen them recover hundreds of millions of dollars since their establishment in 1995. Investors are reminded that seeking the role of lead plaintiff doesn’t diminish the chances of recovering damages; every class member may opt to remain an absent member while still benefiting from potential recoveries.

Faruqi & Faruqi is keen to gather any further information regarding Jasper’s operations from whistleblowers, former employees, or shareholders who might have insights into the company’s conduct. Such information could prove valuable in the ongoing investigation. Interested parties can reach out through the firm's website or contact Wilson directly at the number provided.

To learn more about the investigation and the class action lawsuit against Jasper Therapeutics, investors can visit Faruqi Law's Jasper Class Action page. Furthermore, updates about the case are available on social media platforms like LinkedIn and X, where the firm actively engages with stakeholders and provides timely updates on investor rights and legal proceedings.

As developments unfold around Jasper Therapeutics, affected shareholders are urged to stay informed and utilize their rights as investors. More than ever, the serious nature of these allegations underscores the importance of regulatory compliance and accurate corporate disclosures in maintaining investor trust.